Nicox jumps 11%, following its announcement that annual worldwide net sales of NCX 470 could potentially reach at least $300 million in the eight years following commercial launches in the US and China.

The ophthalmology company cites a US market study conducted by an independent agency, aimed at assessing the commercial potential of its lead product in development for the reduction of intraocular pressure (IOP).

The market study also provided analysis to inform our pricing and reimbursement strategy, which was taken into account in our assessment of potential sales", said Andreas Segerros, CEO of Nicox.

Copyright (c) 2023 CercleFinance.com. All rights reserved.